Introduction
Cancer is a broad term that refers to about 200 diseases that share 7 common characteristics that govern the transformation of normal cells to cancer cells. First, cancer cells stimulate their own growth; second, they resist inhibitory signals that might otherwise stop their growth; third, they resist their own programmed cell death (apoptosis); fourth, they stimulate the growth of blood vessels to supply nutrients to tumors (angiogenesis); fifth, they can multiply forever; sixth, they invade local tissue and spread to distant sites (metastasis); and finally, they have the capacity to invade the immune system (Hanahan and Weinberg, 2011) . Cancer results from a series of molecular events that lead to the alteration of genetic sequence. The genetic alteration may be due to intrinsic agents (e.g., hormones, estrogen), extrinsic agents (e.g., UV radiation, chemical carcinogen), some pathogenic viruses (e.g., human papillomavirus), or bacteria (e.g., Helicobacter pylori). Besides genetic changes, epigenetic modifications (e.g., DNA methylation/acetylation) progressively alter the normal properties of the cells. As these cells grow, they develop new characteristics, including changes in the cell structure, decreased cell adhesion, and the production of new enzymes (Challis and Stam, 1987) . These heritable characteristics allow the cell and its progeny to divide and grow uncontrollably, even in the presence of normal cells in the surroundings that typically inhibit the overgrowth of nearby cells. Such changes allow these cells to spread and invade other tissues. Thus, cells bearing greater amounts of accumulated epigenetic changes (changes in the activity of genes without changes in the genetic sequence) or genetic mutations may escape from the regulated proliferation and acquire the ability to continuously proliferate without further differentiation and apoptosis. The continuous proliferation forms a mass of cells called a "neoplasia". Neoplasias can be classified as either "benign" or "malignant", depending on their nature. In benign neoplasia, the rate of cell proliferation is slow and is confined to the site of origin; these types of cells are called tumor cells. With time and further exposure to intrinsic and extrinsic agents, tumor cells may convert to malignant cells (also called cancer cells), which have a higher rate of proliferation and invasion to the surrounding tissues. Invasion then depends upon the novel adhesive interaction of the malignant cell with the extracellular matrix component of the basement membrane and mesenchymal tissue. Furthermore, cancer cells also make specific heterotypic contacts with endothelial cells to gain access to blood and lymph vessels (Okegawa et al., 2004) . In 1863, Virchow hypothesized that the origin of cancer is at sites of chronic inflammation (Balkwill and Mantovani, 2001) . Indeed, chronic inflammation is a risk factor for tumor development (Chow et al., 2012) . The afflicted tissues are healed by a multifunctional network of chemical signals, which further involves the activation and directed migration of neutrophils, monocytes, and eosinophils to the sites of damage (Chettibi and Ferguson, 1999 ). An environment rich in inflammatory cells, growth factors, activated stroma, and DNA-damage-promoting agents leads to sustained cell proliferation, thus initiating neoplastic risk (Bernestein et al., 2008) . Thus, the immune system can not only suppress tumor growth and cell proliferation; it can also exert selection pressure on tumor cells and facilitate tumor growth by providing a favorable tumor microenvironment (Chow et al., 2012) . Many cells of the immune system are involved in enhancing the growth of tumor cells. T regulatory (Treg) cells play a vital role. Additionally, myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are also known to help the survival and proliferation of tumor cells by immunosuppression. The immunosurveillance hypothesis was formulated in 1950 and suggested that the immune system of the host recognizes antigens of newly arising tumors and eliminates these tumors before they become clinically evident (Burnet, 1957) . Recent work has shown that the immune system may also promote the emergence of primary tumors with reduced immunogenicity that are capable of escaping immune recognition and destruction (Shankaran et al., 2001) . The following paragraphs describe, step by step, the mechanisms of tumor and cancer cell recognition by the immune system, the mechanisms of immunosurveillance, and the escape mechanisms of these cells from immunosurveillance.
Recognition of cancer cells by the immune system
The immune system comprises a network of cells, tissues, and organs working simultaneously to defend the body against attacks by "foreign" invaders. These are primarily microbes (germs): tiny, infection-causing agents such as viruses, mycoplasma, bacteria, parasites, and fungi. The key to a healthy immune system is its remarkable ability to distinguish between the body's own cells as "self " and foreign cells as "nonself " (Houghton, 1994) . The body's immune defenses normally coexist peacefully with cells that carry distinctive "self " marker molecules. However, when immune system cells encounter antigens carrying markers that say "foreign", they quickly launch an attack. Anything that can trigger this immune response is called an immunogen. This may be microbe, such as a virus, or even a mere part of a microbe, such as protein molecule of a microbe (Hougton et al., 2001) . The conversion of a normal cell to a cancerous cell is accompanied by altered surface antigens. The immune system recognizes these altered proteins (antigens) on tumor/cancer cells as foreign antigens and it launches an attack on these cells; this is famously known as tumor immunosurveillance. However, the immune system cannot patrol everywhere to provide body-wide surveillance, flushing out and eliminating all cells that become cancerous. Moreover, tumor cells are devoid of mechanisms to escape from immunosurveillance. In 1909, Ehrlich first proposed that cancer may occur spontaneously in vivo and that the immune system is able to both recognize and protect the organism against cancer cells. About 50 years later, Thomas and Burnet took Ehrlich's idea and proposed that a special type of immune cell, namely the T cell, is the pivotal sentinel in the immune system response against cancer. This contribution led to the coinage of the term "immune surveillance" or "immunosurveillance" to describe the concept where the immune system is on alert against tumor cells (Petrausch et al., 2009 ). In the 1970s, T cells were identified as effector cells and T-cellmediated cellular immunity (which is famously known as T cytotoxic action) was postulated as the "principal process" of tumor immunosurveillance (Naor, 1979) . However, later discoveries proved that cells involved in innate immunity (e.g., natural killer [NK] cells, macrophages, dendritic cells [DCs] ) and even B-cell-mediated humoral responses play a significant role in tumor immunosurveillance. However, there has been growing recognition that the primary tumors are able to escape the immune recognition and destruction by adopting a wide array of escape mechanisms, as described below (Dunn et al., 2002 (Dunn et al., , 2004 .
Escape mechanisms in tumor immunosurveillance
Tumor escape from host immunosurveillance is a concept that was formulated alongside the theory of immunosurveillance (Burnet, 1970) . Mechanisms that may exist for the escape of tumors from immunosurveillance are of course not mutually exclusive but rather a combination of several different characteristics ( Figure) (Real et al., 2001 ): failure to express the major histocompatibility complex (MHC) antigen; decreased and heterogeneous expression of tumor antigen (TA); and abnormal expression of accessory molecules by tumor cells. In addition to these, many other factors allow tumor cells to escape immunosurveillance. Some may escape due to the secretion of soluble factors with immune downregulatory effects by tumor cells or the induction of suppressor cells. Sometimes changes in the T-cell signal transduction molecules lead to escape of the tumor from immunosurveillance (Kim et al., 2007) . (Wölfel et al., 1989) and in vitro (Garcia-Lora et al., 2001 ) in mice. Even when tumor cells do not downregulate all human leukocyte antigen (HLA) alleles, they may completely delete genes encoding some of them (Lehmann et al., 1995) . This theory of escape from immunosurveillance was further studied in a murine model, in which the loss of a single class I allele converted a normally rejected murine tumor to a progressor, despite the fact that MHC alleles were being expressed by the tumor to present tumor antigens. The reason for such loss of recognition was because the tumor antigen, which was originally being presented by the allele that the tumor had lost, was still being recognized by the immune system and this diverted the response from other tumor antigens. Therefore, downregulation of MHC antigens provides a powerful strategy for avoiding T-cell detection (Amiot et al., 1998) .
Decreased and heterogeneous expression of tumor antigens
Antigen-processing defects that also result in HLA expression may affect antigen downregulation. Restifo et al. (1993) directly showed that human tumor cell lines have a defective antigen-processing apparatus, which results in low levels of surface class I MHC and a lack of endogenous antigen expression. The cells had little mRNA for LMP-2, LMP-7, TAP-1, and TAP-2, but these defects were reversible with interferon (IFN)-γ. 
Abnormal expression of accessory molecules by tumor cells
Antitumor responses are commonly triggered by the presentation of the tumor antigen to T cells by host DCs. If an abnormality happens in their function, tumor immunity will be severely affected. In 1996, it was reported that mature DCs from tumor-bearing mice were compromised in their antigen-presenting capacity (Gabrilovich et al., 1996) . Moreover, the development of DCs from a bone marrow precursor was inhibited by tumor-derived soluble products, which suggests that the maturation of antigenpresenting cells can be altered by the tumor.
Secretion of immunosuppressive agents
The serum samples of cancer patients contain immunosuppressive agents, many of which may be acute phase reactants with nonspecific inhibitory properties. Acute phase reactant proteins (APPs) are a large and varied group of glycoproteins in serum released into the bloodstream in response to a variety of stressors. Synthesis of APPs and changes to their composition are fast processes that intervene in the acute phase reaction stage and are present in the initial period and during the evolution of pathological phenomena (e.g., inflammations, trauma, immunopathies, and bacterial or neoplastic disease).
The most significant proteins in this group are C-reactive proteins, fibrinogen, ferritin, serum amyloid protein A, α1-antichymotrypsin, α1-antitrypsin, α1-acid glucoprotein, haptoglobulin, and ceruloplasmin. An increase or decrease in APP serum concentration occurs after 2-4-6 days of disease. The majority of APP quantitative changes are the result of hepatocyte dysfunctions correlated with plasma protein synthesis. There are mostly changes of APP gene transcription induced by cytokines, interleukins, interferons, or tumor necrosis factors (Wigmore et al., 1997) . Reactivity to nontumor antigens may be depressed in cancer patients and contribute to their increased susceptibility to infection (Scheibenbogen et al., 1997) . In 1993, it was reported that melanoma cells express large amounts of CD58, and this inhibits melanoma cell lysis (Altomonte et al., 1993) . CD58 is a novel surface marker that promotes self-renewal of tumor-initiating cells in colorectal cancer. It also exhibits epithelial-mesenchymal transition ability and tumorigenicity, both in vitro and in vivo. Furthermore, activated CD58 upregulates the β-catenin pathway (it is a dual function protein that regulates the coordination of cell-to-cell adhesion as well as gene transcription) and thus promotes self-renewal of colorectal tumor-initiating cells (Yu et al., 2014) . Increased levels of intercellular adhesion molecule 1 (ICAM-1) in the plasma of cancer patients has also been reported in disease progression. ICAM-1, also known as CD54, is a protein in humans that is encoded by the ICAM1 gene. This gene encodes a cell surface glycoprotein that is typically expressed on endothelial cells and cells of the immune system. It binds to integrins of type CD11a, CD11b, and CD8. It is continuously present in low concentrations in the membranes of leukocytes and endothelial cells. Upon cytokine stimulation, the concentrations greatly increase. ICAM-1 can be induced by interleukin-1 (IL-1) and tumor necrosis factor (TNF) and is expressed by the vascular endothelium, macrophages, and lymphocytes. ICAM-1 is a ligand for leukocyte function-associated antigen-1 (LFA-1, integrin), a receptor found on leukocytes. When activated, leukocytes bind to endothelial cells via ICAM-1, then transmigrate into tissues (Rothlein, 1986) . Serum level of soluble Fas measured in patients with hepatocellular carcinoma were found to be significantly higher (median: 4.07 ng/mL) than levels in age-matched healthy donors (0.29 ng/mL). Tumors can also exert some nonspecific suppressive activity by secreting adenosine as a result of their hypoxic metabolism. Adenosine directly suppresses tumoricidal lymphocyte functions (Hoskin et al., 1994) . Adenosine can produce IL-10 by inhibiting IL-12, further contributing to immunosuppressive activity (Link et al., 2000) . IL-10 also downregulates the expression of NK target structures. Tumors also secrete various other cytokines; for example, breast carcinoma predominantly secretes IL-4, IL-6, IL-8, IL-10, TGF-β, and CCL5, while uveal carcinoma secretes IL-6, IL-8, IL-10, IL-17, TNF-α, and vascular endothelial growth factor (VEGF), which influence immune response. Cytokines directly affect tumor growth by acting as growth promoters or growth inhibitors and indirectly affect tumor growth by attracting inflammatory cell types and affecting angiogenesis. With the advent of cloning techniques, recombinant forms of different cytokines have been developed that have emerged as pivotal candidates with significant antitumor potential for cancer therapy. This important goal has been difficult to achieve due to the toxicity of most cytokines, which could not be dissociated from their antitumoral functions (Onfray et al., 2007) . Melanoma cells may secrete IL-15, which enhances expression of the downregulatory NK inhibitory receptor on T cells, as well as possibly depressing the expression of MHC class I molecules on tumor cells (Mingari et al., 1998) . On the other hand, it is also a T-cell growth factor and an antiapoptotic factor. Once again, cytokines have contradictory effects.
Role of T regulatory cells in tumor immunosuppression
Treg cells are a subset of the T-cell population, expressing the high-affinity IL-2 receptor (CD25) (Piccirillo et al., 2002) , cytotoxic T lymphocyte antigen-4 (CTLA-4) (Tai et al., 2012) , glucocorticoid-induced tumor necrosis factor receptor (GITR) (Buechele et al., 2012) , and the lineage-specific transcription factor forkhead box p3 (FOXP3) (Hori et al., 2003) as surface proteins. Treg cells suppressing immune responses via cell-cell interactions and/or the production of suppressor cytokines is currently well established. They are developmentally classified into natural FOXP3 + -expressing Tregs (Tn) generated in the thymus and antigen-induced or adaptive Tregs (Ti) generated in the periphery. Most natural Tregs constitutively express the IL-2 receptor α chain (CD25) and their development and function depend on the expression of the transcription factor FOXP3 (Sakaguchi et al., 2004) . Adaptive Tregs are induced from naïve T cells by specific modes of antigenic stimulation, especially in a particular cytokine milieu (Roncarolo et al., 2006) . (Wild et al., 2010) , lung cancer (Shimizu et al., 2010) , pancreatic cancer (Tan et al., 2009 ), breast cancer (Ma et al., 2012) , liver cancer (Pedroza-Gonzalez et al., 2013), ovarian cancer , and gastrointestinal cancer (Yuan et al., 2011) , either in the circulation or in the tumor itself. Tregs' presence at tumor sites has often been correlated with tolerance induced by the host immune system towards the tumor, leading to a poor prognosis in the cancer patients. Tregs have been implicated in dampening antitumor immunity against malignant cells by suppressing immunological responses to tumor antigens. Tregs that are considerably upregulated in the tumor microenvironment affect both the innate and adaptive immune responses, and hence they induce and maintain immune cell tolerance in the tumor microenvironment. Tregs also exhibit considerable prognostic value; elevated levels of Treg cells are valuable and independent prognostic biomarkers. However, high numbers of Tregs are actually associated with a poor prognosis, as the presence of Tregs in the tumor microenvironment diminishes antitumor immune responses (Badoual et al., 2006; Tao et al., 2012) .
Mechanism of Treg-mediated immune suppression
Treg cells exhibit immune-suppressive activities possibly by 2 mechanisms: 1) cell-cell contact-dependent and 2) cytokine stimulation-dependent. 3.5.1.1. Cell-cell contact These mechanisms involve physical interaction between a Treg cell and the target cell. Treg cells express a number of cell surface-bound factors, such as TGF-β/β1, that interact with ligands such as MHC-II on target cells. The target cells are thus inhibited via direct cell-cell interaction rather than via secreted cytokines (Nakamura et al., 2001 (Borg et al., 2004; Castriconi et al., 2004; Waldhauer and Steinle, 2008) . NK cells are cytolytic cells that recognize and kill malignant cells without prior sensitization, thus serving as the earliest effectors. There is an inverse correlation between NK cell activity and Treg cell expansion in cancer patients (Ghiringhelli et al., 2005) . NK group 2 member D (NKG2D), a NK cell receptor, recognizes various ligands on stressed or damaged cells as in tumors and lyses these cells. CD4 + CD25 + T cells express TGF-β on their surface and inhibit NK cells in a cell-to-cell contact-dependent manner. The inhibition of NK cells is mainly due to the downregulation of NKG2D by TGF-β-expressing Treg cells (Ghiringhelli et al., 2005) . In a similar study in 2010, Zhou et al. found that forced FOXP3 expression in polyclonal CD4 + T cells induced Treg cells and suppressed NK cell functions in a TGF-β-dependent manner. Another cytokine, TGF-β1, has been frequently expressed in tumors (Kong et al., 1996; Hasegawa et al., 2001; Narai et al., 2002) . TGF-β1 expressed on the surface of Treg cells significantly inhibited the surface expression of NKG2D, whereas blocking anti-TGF-β1 mAbs completely restored surface NKG2D to normal levels. These studies concluded that the role of TGF-β and TGF-β1 in inhibiting NK cells was via a cell-to-cell contact mechanism (Lee et al., 2004) . CD4 + CD25 + cells were also found to inhibit DCs. DCs are a pivotal player involved in the initiation of immune reactions by preferably activating naïve T cells (Banchereau and Steinman, 1998) . Treg cells continuously express increased LFA-1 and CTLA-4 at higher levels than naïve T cells (Tn) (Itoh et al., 1999; Read et al., 2000; Salmon et al., 2000; Takahashi et al., 2000) . CTLA-4 upregulates LFA-1-mediated cell adhesion and clustering (Schneider et al., 2000) . CD4 + CD25 + regulatory T cells inhibit DCs via cellto-cell contact in a 2-step process. The initial step involves aggregation of Tregs around DCs dependent on LFA-1 and the second step involves LFA-1-and CTLA-4-dependent active downmodulation of CD80/86 expression on DCs. CD80/86 are important surface coreceptors that greatly enhance DCs' ability to activate T cells. Downregulation of these receptors greatly suppresses immune system (Onishi et al., 2008) . In 2008, Liang et al. reported another putative mechanism of cell-contact inhibition of DCs involving lymphocyte activation gene-3 (LAG-3) engagement of MHC class II. LAG-3 is a CD4-related transmembrane protein expressed by Treg cells. Interaction between LAG-3 and MHC II inhibits DCs. This interaction induces an ITAM-mediated inhibitory signaling pathway, involving FcγRγ and ERK-mediated recruitment of SHP-1 that suppresses DC maturation and its immunostimulatory capacity. Similarly, senescent DCs also exhibited impaired costimulation, suppressed secretion of effector cytokines, and upregulated immune-suppressive molecule PD-L1 (Ye et al., 2013) . These cumulative effects of both senescent T cells and DCs converted into suppressive immune cells have negative regulatory effects on immune responses. Mouse γδ T cells suppressed the immune system via the Fas/Fas ligand pathway and TGF-β/IL-10 secretion (Kapp et al., 2004; Pennington et al., 2005) . A human breast tumor study showed that γδ Treg-mediated immune suppression was due to some unknown soluble factor, independent of TGF-β and IL-10 secretion. γδ Treg cells suppress naïve and effector T-cell function by inhibiting CD4 + , CD8 + , Vg9Vd2 T cells and DCs' maturation and activity (Ye et al., 2013) . The suppressive mechanism implies that TLR8-mediated signaling is involved, as treatment with TLR8 ligands reversed γδ1 Treg cells' suppressive function both in vivo and in vitro (Peng et al., 2005 (Peng et al., , 2007 .
γδ T regulatory cells in tumor immunosuppression
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+ CD25 -FOXP3 Yang et al. (2007) showed that CD4 + CD25 -FOXP3 + naïve T cells in the tumor microenvironment of B lymphoma cells were induced to CD4 + CD25 -FOXP3 + cells. FOXP3+ expression is essential for the development and regulatory activity of T cells (Fontenot et al., 2003; Hori et al., 2003 + CD25 Treg cells are a CD4 + Treg subset characterized by a lack of CD25 and FOXP3 expression that is considerably underexplored. These cells do not secrete IL-10, TGF-β, IL-2, or IFN-γ, but do express membranebound TGF-β1 and an increased percentage of CD122. These cells suppress T-cell proliferation, with CD69-deficient mice having enhanced antitumor immunity (Esplugues et al., 2003) . CD69 has been implicated in apoptosis in monocytes and eosinophils and triggers the inhibitory signal for IL-1 receptor-or CD3-mediated T-cell proliferation (Cosulich et al., 1987; Ramirez et al., 1996; Walsh et al., 1996) . In addition, these cells were recently found to be associated with leukemia relapse after allogeneic hematopoietic stem cell transplantation, suggesting their immune-suppressive potential (Zhao et al., 2013) . The CD69 + CD4 + CD25 -cells mediate immune suppression via membrane-bound TGF-β1 in a cell contact-dependent manner. These cells further activate the MAPK/ERK pathway, which maintains sustainable expression of TGF-B1 and further strengthens the immune suppressive potential of these cells (Han et al., 2009) . (Szkaradkiewicz et al., 2010) . Treg cells produce high levels of IL-10, which restricts NK cells' cytotoxicity by inhibiting production of IFN-γ, IL-2, IL-12, and IL-18 (Wen et al., 1994; Szkaradkiewicz et al., 2010 ). In gastric tumors, H. pylori stimulates high production of proinflammatory cytokines, mainly of IL-1, IL-6, IL-8, and TNF-α (Konturek et al., 2003; Zambon et al., 2005) . T-cell immunoglobulin mucin 3 (TIM-3), an inhibitory molecule expressed by FOXP3 + Tregs, has been speculated to mediate immune suppression through IL-10 secretion.
+ -expressed T regulatory cells in tumor immunosuppression
TIM-3 is a key regulator of dysfunctional or exhausted CD8 + cells. TIM-3 expression in TILs in nonsmall cell lung cancer showed that TIM-3 marks functionally exhausted CD8 + T cells and is likely responsible for immunosurveillance failure (Gao et al., 2012) . TIM-3 + cells frequently coexpress the inhibitory receptor PD-1 and both TIM3 + and PD-1 + result in the generation of dysfunctional/exhausted CD8+ T cells in cancer. TIM3 + Treg cells probably exert immunosuppressive functions by expressing higher levels of effector molecules, such as IL-10, than their TIM3 − counterparts (Sakuishi et al., 2013) . Therefore, decreased NK cell cytotoxicity and elevation of IL-10 serum levels synergistically result in neoplastic transformation and enhanced tumor growth. CD8 + FOXP3 + Treg cells, which are present in elevated levels in prostate, nasopharyngeal, and colorectal cancers (Kiniwa et al., 2007; Chaput et al., 2009; Li et al., 2011) , also actively suppress T-cell proliferation via secretion of IL-10. (Merino et al., 1998; Bandrés et al., 2000) , also mediate immunosuppression via IL-10 release. CD28 + generates a costimulatory signal for the full-fledged activation and survival of CD8+ T cells. CD8 + cells then proliferate into CTL, perform their effector function, and die by apoptosis, while some are retained as memory cells for future antigenic challenge. Due to persistent antigenic challenge and repetitive cycles of stimulation/proliferation, CD28 expression is progressively and irreversibly downregulated on the surface of CD8 + T cells (Kaech et al., 2002; Brenchley et al., 2003) . This leads to the accumulation of highly antigen-experienced CD8 +
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-T cells with shortened telomeres. CD8 + CD28 -Treg cells mediate their immunosuppressive effects by the production of inhibitory cytokines IL-10 (Filaci et al., 2007) or GM-CSF (Tsuchiya et al., 1988; Tsuruta et al., 1998; , hence inhibiting both T-cell proliferation and tumor-specific cytotoxicity. 3.5.1.2.2. IL-35-mediated tumor immunosuppression IL-35 is a heterodimeric cytokine belonging to the IL-12 family, consisting of the Epstein-Barr virus-induced gene-3 and IL-12p35 subunits. IL-35 is highly expressed by mouse FOXP3 + Treg cells (Collison et al., 2007) and stimulated human Treg cells (Chaturvedi et al., 2011; Seyerl et al., 2011) . There are contradictory reports regarding the role of IL-35. While some authors suggest that IL-35 has immunosuppressive potential, others report its antitumorigenic and apoptotic potential. A study by to be an immunosuppressive cytokine that inhibits T cell proliferation and converts naïve T cells into IL-35-producing induced Treg cells. Further IL-35 induced tumor growth by increasing myeloid cell accumulation, enhancing tumor angiogenesis, and blocking antitumor CTL response . In another study, Long et al. showed that IL-35 has antitumor potential, as its overexpression in various human cancer cell lines resulted in cell growth inhibition in vitro. IL-35 overexpression induces G1 cell cycle arrest and increases apoptosis via TNF-α and IFN-γ stimulation and downregulation of cyclin D1, survivin, and Bcl 2 expression (Long et al., 2013 (Li et al., 2011) . CD4 + Th17 cells secreting 1L-17 have also been implicated to have a role in solid tumors. There are contradictory reports regarding the role of IL-17 in tumorigenesis, with some reports asserting that Th17 cells promote tumor growth via the IL-6/STAT3 pathway, upregulation of IL-8, and induction of tumor angiogenesis (Charles et al., 2009; Inozume et al., 2009; Kuang et al., 2010) . However, others suggest that Th17 cells have an antitumor function, as healthy Th17 cells number signify a better outcome.
Role of myeloid-derived suppressor cells in tumor immunosuppression
MDSCs are a heterogeneous population of immature myeloid cells that increase in various cancers. MDSCs have been differentiated into 2 distinct subtypes: granulocytic and monocytic (Schmielau et al., 2001; Zea et al., 2005; Mirza et al., 2006; Filipazzi et al., 2007; Mandruzzato et al., 2009; Poschke et al., 2010; Gowda et al., 2011) . MDSC generation in the bone marrow is induced by various cancer-derived factors, such as G-CSF, IL-6, GM-CSF, IL-1β, prostaglandin E2, TNF-α, and VEGF. These immunosuppressive MDSCs are then recruited to the tumor site by cytokines like CCL2, CXCL12, and CXCL5 (Sawanobori et al., 2008) . The immunosuppressive potential of MDSCs is also dependent on signal transducers, transcription activators (STAT1, STAT3, STAT6), and the nuclear factor kappa light-chain-enhancer of activated B-cell transcription factors (Gabrilovich and Nagaraj, 2009) . MDSCs have a considerable role in immune suppression in the tumor microenvironment, mainly by producing arginase 1, releasing reactive oxygen species (ROS) and nitric oxide (NO), and secreting immunesuppressive cytokines. Arginase is an essential amino acid for T-cell activation. MDSCs sequester arginine and also degrade it by producing arginase 1, hence suppressing CD4 + and CD8 + T cells (Bronte et al., 2003; Kusmartsev et al., 2004; Bronte and Zanovello, 2005) . Another mechanism of MDSC-mediated immune suppression is ROS and peroxynitrite production. ROS and peroxynitrite inhibit CD8 + T cells by catalyzing the nitration of the TCR and preventing T cell-peptide-MHC interactions essential for CD8 + activation (Wiers et al., 2000) . MDSCs have thus emerged as a potential target in cancer immunotherapeutics with triterpenoids (Thimmulappa et al., 2007) , arginase (Serafini et al., 2008) , cyclooxygenase 2 (Sinha et al., 2007) , phosphodiesterase-5 inhibitors (Serafini et al., 2006) , and nitroaspirin (Nagaraj et al., 2010; Molon et al., 2011; Mundy-Bosse et al., 2011) (Mills et al., 2000) . The poor antigen-presenting capability of TAMs accounts for their immune-suppressive functions. TAMs are found in elevated levels in the tumor microenvironment and are responsible for tumor growth, survival, progression, and metastasis. TAMs stimulate tumor angiogenesis by secreting various proangiogenic and immunosuppressive cytokines such as IL-10 and CCL2 (Biswas and Mantovani, 2010; Corzo et al., 2010; Qian and Polard, 2010) . In 2011, Daurkin et al. showed that TAMs isolated from renal cell carcinoma (RCC) tumors had a high 15-lipoxygenase-2 (15-LOX2) expression and secreted substantial amounts of 15(S)-hydroxyeicosatetraenoic acid, its major bioactive lipid product. TAMs isolated from RCC were capable of inducing T lymphocytes, FOXP3 + , and CTLA-4 coreceptor. This TAM-induced FOXP3 and CTLA-4 expression in T cells was independent of lipoxygenase and could not be reversed by inhibiting lipoxygenase activity (Daurkin et al., 2011) . Thus, 15-LOX2 expression enhances the immunosuppressive potential of TAMs as well as Treg cells. In another study in 2006, Luo et al. reported that legumain, a novel acidic cysteine endopeptidase of the C13 family of cysteine proteases, was responsible for the immunosuppressive attributes of TAMs in breast cancer (Lin et al., 2013) . Legumain encoded by the asparaginyl endopeptidase gene was found to be highly upregulated in many murine and human tumor tissues (Liu et al., 2003; Murthy et al., 2005) , leading to increased tumor progression, angiogenesis, and metastasis.
Conclusion
The human immune system uses a complex array of putative mechanisms to combat exogenous as well endogenous antigens. Tumor cells in the body express specialized antigens, specifically in the tumor microenvironment. Such cells expressing these antigens are recognized as alien molecules by the immune system and it employs complex biomechanisms ensuring rectification. This process is known as immunosurveillance. However, certain cells, such as Treg cells, MDSCs, and TAMs, dodge this immunosurveillance and contribute to tumor growth, survival, proliferation, and metastasis. These cells express surface markers including FOXP3, CTLA, GITR, CD28 + effector T-cell proliferation by hindering antigen presentation by NK cells or DCs, or secreting inhibitory cytokines such as IL-10, IL-35, IL-17, or TGF-β/β1. These various subsets of CD4 + CD8 + T cells, TAMs, and MDSCs represent novel targets in deciphering the biology of the tumor microenvironment, under which they modulate and suppress the host's immune response against tumor cells. Targeting these surface markers is a potential strategy in cancer immunotherapy. Understanding these concepts of immunology may lead to potential strategies to modulate immunosuppressive effects in the field of cancer research.
